Meridia® is pulled from US Market
Peterson & Associates, P.C. is dedicated to help patients who have suffered heart damage associated with the use of Meridia®. If you or someone you know has suffered from Meridia®, please contact us.
On October 8th, 2010, the drug maker Abbott Laboratories and the FDA announced that it will withdraw Meridia from the US Market.
According to the FDA website, Meridia was approved November 1997 for weight loss and maintenance of weight loss in obese people, as well as in certain overweight people with other risks for heart disease. The approval was based on clinical data showing that more people receiving sibutramine lost at least 5 percent of their body weight than people on placebo who relied on diet and exercise alone.
FDA has now requested market withdrawal after reviewing data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT). SCOUT is part of a post market requirement to look at cardiovascular safety of sibutramine after the European approval of the drug. The trial demonstrated a 16 percent increase in the risk of serious heart events, including non-fatal heart attack, non-fatal stroke, the need to be resuscitated once the heart stopped, and death, in a group of patients given sibutramine compared with another given placebo. There was a small difference in weight loss between the placebo group and the group that received sibutramine.
FDA's RECOMMENDATION: Physicians are advised to stop prescribing Meridia to their patients, and patients should stop taking this medication. Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs.
At Peterson & Associate, P.C. we are determined to get justice for the victims of Meridia® and to seek compensation for their suffering.
If you or someone you know has suffered from Meridia®, please contact us immediately.